Choreño PJA, Guadarrama OP

Language: Spanish
References: 7
Page: 7-10
PDF size: 339.11 Kb.

ABSTRACT

Glioblastoma is among the most aggressive primary tumors of the central nervous system due to its high capacity to acquire resistance to many of the currently available oncologic treatments. Likewise, this tumor possesses an elevated potential for recurrence generating a high mortality among affected individuals. Therefore, there is an urgent necessity for new therapeutic strategies to achieve a higher remission rate and a better survival rate in patients with glioblastoma. New advances in immunotherapy, such as the production of autologous T lymphocytes modified by genetic engineering, are promissory therapeutic agents capable of providing a considerable degree of control over different types of cancers. In this article, we discuss the results of some recent studies on the specific use of this strategy for the management of individuals with glioblastoma.

REFERENCES

1. Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015. Neuro Oncol. 2018;20 (Suppl 4):iv1-iv86. doi: 10.1093/neuonc/noy131.

2. Roy S, Lahiri D, Maji T, Biswas J. Recurrent Glioblastoma: Where we stand. South Asian J Cancer. 2015;4(4):163-73.

3. Davila ML, Brentjens RJ. CD19-Targeted CAR T Cells as Novel Cancer Immunotherapy for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia. Clin Adv Hematol Oncol. 2016;14(10):802-8.

4. Brown CE, Alizadeh D, Starr R, Weng L, Wagner L, Naranjo A, et al. Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. N Engl J Med. 2016; 375(26):2561-9.

5. O´Rourke DM, Desai A, Morrissette J, Martinez-Lage M, Nasrallah ML, Brem S, et al. Pilot study of T cells redirected to EGFRvIII with a chimeric antigen receptor in patients with EGFRvIII+ gioblastoma. Neuro Oncol. 2015;17(Suppl 5):v110-v111.

6. Ahmed N, Brawley V, Hegde M, Bielamowicz K, Wakefield A, Ghazi A, et al. Autologous HER2 CMV bispecific CAR T cells are safe and demonstrate clinical benefit for glioblastoma in a Phase I trial. Journal for ImmunoTherapy of Cancer. 2015;3(Suppl 2):O11.

7. O´Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med 2017; 9(399):eaaa0984.